Pinnacle Medicines secured an $89 million Series B co-led by LAV and Foresite Capital to advance its oral peptide programs. The funding brings Pinnacle’s total capital raised to $134 million and underscores investor appetite for oral peptide formats that can expand beyond parenteral biologics. The round includes participation from Quan Capital, Hankang Capital, RA Capital Management, Logos Capital and existing investor Orbimed, aligning U.S. and China-linked capital with early-stage platform development. Pinnacle’s focus keeps the pipeline centered on transforming peptide therapeutics into oral medicines. The financing adds runway for IND-enabling work and early clinical progress, critical for companies trying to prove oral delivery durability and therapeutic consistency.